Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2021

Nov 12, 2021

SELL
$1.91 - $3.05 $1.84 Million - $2.94 Million
-962,932 Closed
0 $0
Q1 2021

May 14, 2021

BUY
$3.5 - $4.56 $3.37 Million - $4.39 Million
962,932 New
962,932 $3.91 Million

Others Institutions Holding MDNA

About Medicenna Therapeutics Corp.


  • Ticker MDNA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 69,637,504
  • Market Cap $21.6M
  • Description
  • Medicenna Therapeutics Corp., an immunotherapy company, engages in the development and commercialization of Superkines and empowered Superkines for the treatment of cancer and other diseases. Its lead product is MDNA55, an interleukin- 4 (IL-4) EC that has completed Phase IIb clinical trial for the treatment of recurrent glioblastoma, as well as...
More about MDNA
Track This Portfolio

Track Board Of Trustees Of The Leland Stanford Junior University Portfolio

Follow Board Of Trustees Of The Leland Stanford Junior University and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Board Of Trustees Of The Leland Stanford Junior University, based on Form 13F filings with the SEC.

News

Stay updated on Board Of Trustees Of The Leland Stanford Junior University with notifications on news.